Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma

Pediatric Blood and Cancer

Volumn 61, Issue 11, 2014, Pages 2096-2098

  Wagner, Lars M ^a   Yin, Hong ^a   Eaves, David ^a   Currier, Mark ^a   Cripe, Timothy P ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Abraxane; Cav 1; Ewing sarcoma; Nab paclitaxel; Osteosarcoma; SPARC

Indexed keywords

GEMCITABINE; OSTEONECTIN; PACLITAXEL; ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; NANOPARTICLE; SPARC PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG SCREENING; EWING SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; BONE NEOPLASMS; CHILD; SARCOMA, EWING; TUMOR CELL LINE;

ALBUMINS; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MICE; NANOPARTICLES; OSTEONECTIN; OSTEOSARCOMA; PACLITAXEL; SARCOMA, EWING;

EID: 84922625708     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25062     Document Type: Article

References (20)

1. Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: A new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 2007; 7:919-943.
2. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007; 7:850-856.
3. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12:1317-1324.
4. Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008; 19:899-909.
5. Tai IT, Tang MJ. SPARC in cancer biology: Its role in cancer progression and potential for therapy. Drug Resist Update 2008; 11:231-246.
6. Desai N, Trieu V, Damascelli B, et al. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009; 2:59-64.
7. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol 2011; 29:4548-4554.
8. Mayordomo E, Machado I, Giner F, et al. A tissue microarray study of osteosarcoma: Histopathologic and immunohistochemical validation of xenotransplanted tumors as preclinical models. Appl Immunohistochem Mol Morphol 2010; 18:453-461.
9. Yang Y, Niu X, Zhang Q, et al. The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine. Am J Med Sci 2012; 344:199-205.
10. Patel SR, Papadopoulos NE, Plager C, et al. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer 1996; 78:741-744.
11. McTiernan A, Whelan JS. A phase II study of docetaxel for the treatment of recurrent osteosarcoma. Sarcoma 2004; 8:71-76.
12. Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004; 22:1706-1712.
13. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008; 113:419-425.
14. Frese KY, Neesse A, Cook N, et al. Nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discovery 2012; 2:260-269.
15. Roy V, LaPlant RB, Gross GG, et al. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Ann Oncol 2009; 20:449-453.
16. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-1703.
17. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score for immunohistochemical estrogen receptor detection in breast cancer tissue. Pathologie 1987; 8:138-140.
18. Shao H, Tang H, Salavaggione OE, et al. Improved response to nab-paclitaxel compared with cremaphor-solubilized paclitaxel is independent of Secreted Protein Acidic and Rich in Cysteine expression in non-small cell lung cancer. J Thorac Oncol 2011; 6:998-1005.
19. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27:3611-3619.
20. Zhang L, Marrano P, Kumar S, et al. Abraxane (nab-paclitaxel) is an active drug in preclinical model of pediatric solid tumors. Clin Cancer Res 2013; 19:5972-5983.